Zoetis is trading 6.33% down at $72.38 after investors reacted to its August 6 earnings release and sharply reduced 2026 outlook.
- Second-quarter revenue was $2.47 billion, missing estimates; U.S. Companion Animal sales declined 11% amid weaker clinic visits, price sensitivity, and intensifying competition.
- Full-year revenue guidance fell to $9.12–$9.32 billion and adjusted EPS guidance to $6.15–$6.25 billion.
- Zoetis is underperforming a broadly stronger market, with major indices higher on August 7, 2026; trading activity is elevated.